西藏诺迪康药业股份有限公司 董事和高级管理人员所持本公司股份及其变动管理规则 （2025年8月修订） 第一章 总则 第一条 为加强对西藏诺迪康药业股份有限公司（以下简称"公司""本公司"）董 事和高级管理人员所持公司股份及其变动情况的申报、披露与监督，根据《中华人民共和 国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券 法》"）、中国证监会《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》 《上海证券交易所上市公司自律监管指引第15号——股东及董事、高级管理人员减持股份》 及公司章程的相关规定，制定本规则。 第二条 本规则适用于公司董事和高级管理人员所持公司股份及其变动的管理。公司 董事和高级管理人员应当遵守《公司法》《证券法》和有关法律、行政法规，中国证监会 规章、规范性文件以及证券交易所规则中关于股份变动的限制性规定。公司董事和高级管 理人员就其所持股份变动相关事项作出承诺的，应当严格遵守。 第三条 公司董事和高级管理人员所持本公司股份，是指登记在其名下和利用他人账 户持有的所有公司股份。董事和高级管理人员从事融资融券交易的，还包括记载在其信用 账户内的公司股份。 ...

Core Viewpoint - Xizang Pharmaceutical (600211) reported a slight increase in revenue for the first half of 2025, but a decline in net profit, indicating potential challenges in profitability despite stable sales growth in its main product [1] Financial Performance - The company's revenue for the first half of 2025 reached 1.651 billion yuan, representing a year-on-year growth of 2.23% [1] - The net profit attributable to shareholders was 567 million yuan, showing a year-on-year decrease of 8.96% [1] - The company plans to distribute a cash dividend of 8.81 yuan per 10 shares (including tax) [1] Product Sales - Sales revenue from the main product, Xinhua Su, amounted to 1.456 billion yuan, reflecting a year-on-year growth of 0.41% [1]

Core Viewpoint - Xizang Pharmaceutical (600211.SH) reported a mixed performance in its semi-annual report, with a slight increase in revenue but a decline in net profit [1] Financial Performance - The company achieved operating revenue of 1,650.71 million yuan, representing a year-on-year growth of 2.23% [1] - The net profit attributable to shareholders decreased by 8.96% to 567.32 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 542.84 million yuan, showing a year-on-year increase of 3.69% [1] Product Sales - Sales revenue from the main product, Xinhuasu, was 1,455.73 million yuan, reflecting a year-on-year growth of 0.41% [1] - Revenue from other products reached 191.69 million yuan, marking a significant year-on-year increase of 18.83% [1] Dividend Distribution - The company announced a cash dividend of 8.81 yuan per 10 shares to all shareholders [1]

西藏药业公告，2025年上半年营业收入16.51亿元，同比增长2.23%。净利润5.67亿元，同比下降 8.96%。公司拟以实施利润分配方案之股权登记日可参与分配的总股本为基数，向全体股东每10股派发 现金红利8.81元（含税）。 ...

从资金流向上来看，当日生物制品板块主力资金净流出7.15亿元，游资资金净流入1.03亿元，散户资金净 流入6.12亿元。生物制品板块个股资金流向见下表： 证券之星消息，8月12日生物制品板块较上一交易日下跌0.65%，科兴制药领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600211 | 西藏药业 | 48.04 | 10.01% | 17.50万 | | 8.33亿 | | 300357 | 我武生物 | 26.60 | 2.19% | 11.16万 | | 2.91亿 | | 002007 | 华兰生物 | 17.06 | 1.73% | 36.57万 | | 6.30亿 | | 301080 | 百普赛斯 | 54.16 | 0.86% | 2.12万 | | 1.14亿 | | 002581 | ST未名 | 7.27 | 0.83% | ...

近日，工业和信息化部等七部门印发《关于推动脑机接口产业创新发展的实施意见》，提出，到2027 年，脑机接口关键技术取得突破，初步建立先进的技术体系、产业体系和标准体系。电极、芯片和整机 产品性能达到国际先进水平，脑机接口产品在工业制造、医疗健康、生活消费等加快应用。产业规模不 断壮大，打造2至3个产业发展集聚区，开拓一批新场景、新模式、新业态。到2030年，脑机接口产业创 新能力显著提升，形成安全可靠的产业体系，培育2至3家有全球影响力的领军企业和一批专精特新中小 企业，构建具有国际竞争力的产业生态，综合实力迈入世界前列。 国元证券指出，脑机接口通过在脑与机器之间建立信息通道，实现生物智能与机器智能的协同交互，是 生命科学和信息科学融合发展的前沿技术。当前，脑机接口创新成果持续涌现，产业加速壮大，正孕育 颠覆性突破，已成为科技创新和产业创新深度融合的重要领域。随着脑机接口技术加速发展，产业政策 日趋明晰，已有北京、上海、南京、四川、山东等省区市发布了相关政策，同时一些医疗机构、企业也 加速推进脑机接口的创新技术研发，产业链中上游的技术进步带来下游应用端不断突破，国内脑机接口 公司有望逐步实现商业化应用，并向产 ...

Group 1 - The flu concept sector declined by 0.50%, ranking among the top declines in the concept sectors, with companies like Qizheng Tibetan Medicine, New Light Pharmaceutical, and Weikang Pharmaceutical experiencing significant drops [1][2] - Among the flu concept stocks, 56 stocks saw price increases, with Chengyi Pharmaceutical, Kehua Bio, and Guilin Sanjin leading with gains of 10.04%, 10.00%, and 10.00% respectively [1][2] Group 2 - The flu concept sector experienced a net outflow of 2.651 billion yuan, with 116 stocks seeing net outflows, and 11 stocks having outflows exceeding 50 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 909 million yuan, followed by Tibet Pharmaceutical, Yipinhong, and Zhendong Pharmaceutical [2][3] Group 3 - The top inflow stocks in the flu concept sector included Guilin Sanjin, Borui Pharmaceutical, and Kehua Bio, with net inflows of 948.599 million yuan, 871.114 million yuan, and 772.718 million yuan respectively [2][7] - The overall market performance showed a mixed trend, with various sectors experiencing different levels of gains and losses, indicating a volatile market environment [2][6]

Market Overview - The biopharmaceutical sector increased by 0.55% on August 4, with Sairun Biotech leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in Biopharmaceutical Sector - Sairun Biotech (688163) closed at 27.37, up 11.90% with a trading volume of 72,700 shares and a transaction value of 190 million [1] - Xizang Pharmaceutical (600211) closed at 46.19, up 10.00% with a trading volume of 321,400 shares and a transaction value of 1.451 billion [1] - Wanze Shares (000534) closed at 17.31, up 9.97% with a trading volume of 598,100 shares and a transaction value of 1.018 billion [1] - Other notable gainers include Saiseng Pharmaceutical (300485) and Sanyuan Gene (837344) with increases of 7.45% and 6.89% respectively [1] Top Losers in Biopharmaceutical Sector - Kexing Pharmaceutical (688136) closed at 50.20, down 9.42% with a trading volume of 129,900 shares and a transaction value of 655 million [2] - Aopumai (688293) closed at 57.00, down 6.56% with a trading volume of 20,800 shares and a transaction value of 119 million [2] - Other significant decliners include Wuxi Jinghai (836547) and Olin Biotech (688319) with decreases of 3.28% and 3.22% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 10.35 million from institutional investors, while retail investors contributed a net inflow of 250 million [2][3] - Notable net inflows from individual stocks include Ganjin Pharmaceutical (603087) with 18.6 million and Xizang Pharmaceutical (600211) with 12.1 million [3] - Conversely, significant net outflows were observed in stocks like Xizang Pharmaceutical and Wanze Shares, indicating a mixed sentiment among retail investors [3]

证券之星消息，7月31日生物制品板块较上一交易日上涨0.05%，安科生物领涨。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300009 | 安科生物 | 12.11 | 20.02% | 330.56万 | | 38.34亿 | | 688136 | 科兴制药 | 53.25 | 13.15% | 19.24万 | | 9.56亿 | | 688278 | 特宝生物 | 91.33 | 7.46% | 12.10万 | | 11.04亿 | | 300841 | 康华生物 | 77.47 | 5.76% | 11.37万 | | 8.67亿 | | 688293 | 奥浦迈 | 60.50 | 5.38% | 2.60万 | | 1.58亿 | | 301393 | 吴帆生物 | 61.69 | 4.86% | 7.17万 | | 4.37亿 | ...

金融界消息 截至2025年7月31日收盘，西藏药业（600211）报收于42.58元，上涨2.92%，换手率6.2%， 成交量19.98万手，成交金额8.52亿元。 资金流向方面，今日主力资金净流入5940.67万元，占比成交额6.97%。其中，超大单净流入3358.29万 元、占成交额3.94%，大单净流入2582.38万元、占成交额3.03%，中单净流出流入182.44万元、占成交 额0.21%，小单净流出6123.10万元、占成交额7.18%。 西藏药业最新一期业绩显示，截至2025一季报，公司营业总收入7.12亿元、同比增长1.12%，归属净利 润2.69亿元，同比减少13.95%，扣非净利润2.53亿元，同比增长7.90%，流动比率3.861、速动比率 3.720、资产负债率20.79%。 天眼查商业履历信息显示，西藏诺迪康药业股份有限公司，成立于1999年，位于拉萨市，是一家以从事 医药制造业为主的企业。企业注册资本32231.9196万人民币，实缴资本6992万人民币。公司法定代表人 为陈达彬。 通过天眼查大数据分析，西藏诺迪康药业股份有限公司共对外投资了20家企业，参与招投标项目2583 次， ...